Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer
21 5월 2024 - 9:05PM
Business Wire
– Mr. Hanley brings over two decades of
leadership experience in product development and commercialization
across a wide range of neuropsychiatric indications, including
major depressive disorder and schizophrenia –
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced
the expansion of the Company’s leadership team with the addition of
industry veteran Michael Hanley as chief operating officer (COO).
Mr. Hanley brings over twenty-five years of leadership experience
in the life sciences industry, with established expertise across
corporate operations, product development, strategy, and
commercialization, with relevant expertise in
CNS/neuroscience-focused companies. As Alto’s COO, Mike will be
responsible for new product planning, portfolio strategy, and
cross-functional leadership to maximize the impact of the Company’s
clinical-stage programs and biomarker platform.
“Mike has dedicated his career to leading the product life cycle
for companies in CNS and psychiatry, from early-stage planning and
portfolio strategy through launch and brand management,” said Amit
Etkin, M.D., Ph.D., founder and chief executive officer of Alto.
“His expertise will be instrumental as we advance into late-stage
clinical development and execute on our mission to bring targeted
treatments to those in need. At Alto we aim to develop each of our
programs based on sound scientific, strategic, and commercial
considerations; we believe adding Mike to the team at this juncture
will further our ability to do this across our broad pipeline.”
Prior to joining Alto, Mr. Hanley served as chief commercial
officer and chief business officer at Aeglea BioTherapeutics.
Previously, he was the general manager at Horizon Therapeutics and
head of U.S. sales for Lundbeck’s psychiatry business unit, where
he was responsible for managing TRINTELLIX (vortioxetine), ABILIFY
MAINTENA (aripiprazole), and preparing for the launch of REXULTI
(brexpiprazole). Throughout his career, Mr. Hanley has worked in,
and held leadership roles across, various therapeutic areas
including major depressive disorder, schizophrenia, sleep
disorders, epilepsy, Alzheimer’s disease, Parkinson’s disease, and
amyotrophic lateral sclerosis. Mr. Hanley received a Bachelor of
Business Administration in Marketing from the University of Notre
Dame and a Master of Business Administration from the Kellogg
School of Management at Northwestern University.
“Alto is a mission-driven company dedicated to transforming
mental health treatments, and I am eager to join a team that has a
strong scientific acumen and proven track record in the field,”
added Mr. Hanley. “I look forward to leveraging my knowledge in CNS
and operational experience to maximize the potential of our
precision psychiatry platform and help advance our pipeline toward
a number of important near-term clinical data readouts.”
About Alto Neuroscience
Alto Neuroscience is a clinical-stage biopharmaceutical company
with a mission to redefine psychiatry by leveraging neurobiology to
develop personalized and highly effective treatment options. Alto’s
Precision Psychiatry Platform™ measures brain biomarkers by
analyzing EEG activity, neurocognitive assessments, wearable data,
and other factors to better identify which patients are more likely
to respond to Alto product candidates. Alto’s clinical-stage
pipeline includes novel drug candidates in depression, PTSD,
schizophrenia, and other mental health conditions. For more
information, visit www.altoneuroscience.com or follow Alto on
X.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240521805369/en/
Investor Contact Nick Smith
investors@altoneuroscience.com
Media Contact Jordann Merkert
media@altoneuroscience.com
Alto Neuroscience (NYSE:ANRO)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Alto Neuroscience (NYSE:ANRO)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024